T-Dxd was also granted accelerated FDA approval for metastatic treatment-refractory NSCLC in August 2022, after analysis of the DESTINITY-Lung01 trial (NCT03505710) results, a multicenter, international, phase II study of patients with metastatic HER2-mutant NSCLC that was refractory to standard treatment. Here, ERBB2 is linked to non-small cell lung carcinoma.